5,522 Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Machina Capital S.A.S.

Machina Capital S.A.S. boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 236.5% in the third quarter, HoldingsChannel reports. The firm owned 7,857 shares of the biopharmaceutical company’s stock after buying an additional 5,522 shares during the period. Machina Capital S.A.S.’s holdings in Alnylam Pharmaceuticals were worth $1,939,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. New York Life Investment Management LLC boosted its position in Alnylam Pharmaceuticals by 9.7% in the third quarter. New York Life Investment Management LLC now owns 4,722 shares of the biopharmaceutical company’s stock worth $1,165,000 after purchasing an additional 418 shares during the last quarter. AlphaCore Capital LLC purchased a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $325,000. Fulcrum Asset Management LLP bought a new position in Alnylam Pharmaceuticals during the third quarter worth about $1,602,000. Allspring Global Investments Holdings LLC boosted its position in Alnylam Pharmaceuticals by 3.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,644 shares of the biopharmaceutical company’s stock worth $611,000 after purchasing an additional 98 shares during the period. Finally, Brighton Jones LLC boosted its position in Alnylam Pharmaceuticals by 42.2% during the third quarter. Brighton Jones LLC now owns 6,967 shares of the biopharmaceutical company’s stock worth $1,719,000 after purchasing an additional 2,069 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 2.0%

Shares of Alnylam Pharmaceuticals stock opened at $156.65 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $149.18 and a 1 year high of $479.79. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.48 and a quick ratio of 2.43. The firm has a market cap of $20.98 billion, a PE ratio of 8.13 and a beta of 0.42. The company has a 50 day simple moving average of $221.24 and a two-hundred day simple moving average of $276.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same period in the previous year, the business earned $2.90 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.85 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ALNY. Wells Fargo & Company reduced their target price on shares of Alnylam Pharmaceuticals from $253.00 to $220.00 and set an “equal weight” rating for the company in a research note on Friday, October 30th. The Goldman Sachs Group cut their price objective on shares of Alnylam Pharmaceuticals from $536.00 to $320.00 and set a “buy” rating for the company in a report on Friday, October 30th. JPMorgan Chase & Co. cut their price objective on shares of Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating for the company in a report on Wednesday, September 30th. Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating for the company in a research note on Friday, October 30th. Finally, TD Cowen lowered their target price on shares of Alnylam Pharmaceuticals from $482.00 to $354.00 and set a “buy” rating on the stock in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $305.86.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.